⏳ Fetching live dividend data...
Home › Calculator › ENZ Dividend Calculator 2026
Enzo Biochem, Inc. · NYSE
Price: $0.31 · Annual div: $0.40/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in ENZ → $8018983419452.46M in 10 years · $667,737,056,060,674,200.00/month
Enzo Biochem, Inc. is a diversified enterprise that encompasses diagnostics, clinical laboratory services, and life sciences. The company's core activities involve the entire process of researching, developing, manufacturing, and commercializing diagnostic and scientific investigation products, drawing upon advancements in genetic engineering, biotechnology, and molecular biology. Its operations are organized into three primary segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products division is responsible for creating, producing, and distributing vital tools and reagents tailored for customers in clinical research, pharmaceutical development, and broader bioscience research. Its extensive product catalog features items such as proteins, antibodies, peptides, small molecules, labeling agents, dyes, and various kits. These offerings provide life science researchers with the means for target identification and validation, content analysis, gene expression studies, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also supplies specialized solutions to scientific experts investigating critical health areas, including cancer, cardiovascular ailments, neurological disorders, metabolic conditions (like diabetes and obesity), endocrine imbalances, infectious and autoimmune diseases, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment delivers a comprehensive spectrum of molecular and other clinical laboratory tests and procedures. These are utilized by physicians in routine patient care to help confirm or establish diagnoses, monitor the effectiveness of treatments or medications, and identify previously undiagnosed medical conditions. This division operates a central, full-service clinical laboratory in Farmingdale, New York, complemented by a network of 30 patient service centers across New York and New Jersey. Additionally, it runs dedicated "STAT" or rapid-response laboratories in New York City and Connecticut, alongside a full-service phlebotomy facility and an internal logistics department. The Therapeutics segment is dedicated to pioneering novel treatment approaches within the fields of gastrointestinal, infectious, ophthalmic, and metabolic diseases. Enzo Biochem distributes its array of products and services through its dedicated internal sales team and an extensive network of distributors, reaching both domestic and international markets. The company was established in 1976 and has its corporate headquarters situated in New York, New York.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open ENZ position with:
Real after-tax yield depends on where you live and how you hold ENZ.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 127.47% | 124.67% | $12,747 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 108.35% | 105.55% | $10,835 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 101.98% | 99.18% | $10,198 / yr |
| 🇬🇧 UK ISA | 0% | 127.47% | 124.67% | $12,747 / yr |
| 🇬🇧 UK Taxable | 8.75% | 116.32% | 113.52% | $11,632 / yr |
| 🇨🇦 TFSA | 0% | 127.47% | 124.67% | $12,747 / yr |
| 🇨🇦 CA Taxable | 25% | 95.60% | 92.80% | $9,560 / yr |
| 🇦🇺 Super (pension) | 15% | 108.35% | 105.55% | $10,835 / yr |
| 🇦🇺 AU Taxable | 30% | 89.23% | 86.43% | $8,923 / yr |
| 🇩🇪 DE Taxable | 26.375% | 93.85% | 91.05% | $9,385 / yr |
| 🇫🇷 FR Taxable | 30% | 89.23% | 86.43% | $8,923 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $0.40/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
ENZ pays quarterly — 4 times per year. Next ex-div: TBD.
How ENZ compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for ENZ sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Other | 2022-10-28 | 75,000 | $2.50 | $187.5K | ||
| Other | 2022-10-28 | 80,700 | $5.00 | $403.5K | ||
| Other | 2022-10-28 | 75,000 | $7.50 | $562.5K | ||
| Other | 2022-10-28 | 30,000 | $2.50 | $75.0K | ||
| Other | 2022-10-28 | 34,500 | $5.00 | $172.5K | ||
| A-Award | 2020-02-24 | 55,400 | $2.20 | $121.9K | ||
| A-Award | 2020-02-24 | 130,100 | $2.20 | $286.2K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Revenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the ENZ dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Enzo Biochem, Inc. (ENZ) is currently trading at $0.31, trading near its 52-week low. The current dividend yield is 127.47% based on an annual payout of $0.40 per share.
Enzo Biochem, Inc. (ENZ) is a healthcare stock currently trading at $0.31 with a dividend yield of 127.47%. The company pays an annual dividend of $0.40 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →